Insider · CIK 0001843539
John Celebi
Files at FTH (Sensei Biotherapeutics, Inc.). First filing -, latest -.
In brief
John Celebi files SEC Form 4 as CEO, president and director at FTH (Sensei Biotherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Celebi has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 24, 2026 | FTH Sensei Biotherapeutics, Inc. | 3,374 0.27% of outstanding | $116k | Feb 24, 2026 | $1.1M |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | FTH Sensei Biotherapeutics, Inc. | FTax withholding Common Stock | -5,558 | $0.48 | $2,646 | 105,862 | Feb 26, 2025 |
| Feb 14, 2025 | FTH Sensei Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +360,000 | $0.00 | $0 | 360,000 | Feb 14, 2025 |
| Dec 20, 2024 | FTH Sensei Biotherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +355,000 | $0.00 | $0 | 355,000 | Dec 23, 2024 |
Questions about John Celebi
Answered from the filings on this page, as of the latest one.
Is John Celebi buying or selling?
John Celebi has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Celebi's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Celebi has 0.
Where does John Celebi file Form 4?
John Celebi has filed Form 4 at FTH (Sensei Biotherapeutics, Inc.) as PRESIDENT AND CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.